Dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with AKT inhibitor MK2206 in esophageal carcinoma cells

被引：0
|
作者：
Yu, Hao [1 ]
Shi, Ni [1 ]
Pan, Zui [1 ]
Chen, Tong [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1253
引用
收藏
页数：1
相关论文
共 50 条
  • [31] NVP-BEZ235, a dual inhibitor of PI3K and mTOR, induces MAPK phosphorylation in HER2 positive cells
    Serra, Violeta
    Eichhorn, Pieter
    Scaltriti, Maurizio
    Prudkin, Ludmila
    Rodriguez, Olga
    Guzman, Marta
    Baselga, Jose
    CANCER RESEARCH, 2009, 69
  • [32] Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models
    Uestuen, Sevdican
    Lassnig, Caroline
    Preitschopf, Andrea
    Mikula, Mario
    Mueller, Mathias
    Hengstschlaeger, Markus
    Weichhart, Thomas
    TRANSPLANT IMMUNOLOGY, 2015, 33 (01) : 45 - 50
  • [33] Dual PI3K/mTOR inhibitor NVP-BEZ235 decreases the proliferation of doxorubicin-resistant K562 cells
    Li, Jie
    Wang, Xiaozi
    Ma, Chuanbao
    Xu, Shasha
    Xu, Mengyao
    Yang, Jie
    Wang, Ruicang
    Xue, Liying
    MOLECULAR MEDICINE REPORTS, 2021, 23 (04)
  • [34] NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Serra, Violeta
    Markman, Ben
    Scaltriti, Maurizio
    Eichhorn, Pieter J. A.
    Valero, Vanesa
    Guzman, Marta
    Luisa Botero, Maria
    Llonch, Elisabeth
    Atzori, Francesco
    Di Cosimo, Serena
    Maira, Michel
    Garcia-Echeverria, Carlos
    Lluis Parra, Josep
    Arribas, Joaquin
    Baselga, Jose
    CANCER RESEARCH, 2008, 68 (19) : 8022 - 8030
  • [35] Inhibition of DNA repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a novel radiosensitization strategy for glioblastoma
    Del Alcazar, Carlos Gil
    Gillam, Molly
    Tomimatsu, Nozomi
    Gao, Xiaohuan
    Mukherjee, Bipasha
    Burma, Sandeep
    CANCER RESEARCH, 2013, 73 (08)
  • [36] In vivo antitumor activity of NVP-BEZ235, a dual PI3K/mTOR inhibitor, and RAD001 (everolimus), an mTOR inhibitor, in endometrial cancer
    Shoji, Keiko
    Oda, Katsutoshi
    Nakagawa, Shunsuke
    Ikeda, Yuji
    Kashiyama, Tomoko
    Miyamoto, Yuichiro
    Tanikawa, Michihiro
    Kuramoto, Hiroyuki
    Hiraike-Wada, Osamu
    Yano, Tetsu
    Taketani, Yuji
    CANCER RESEARCH, 2011, 71
  • [37] Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
    Shoji, Keiko
    Oda, Katsutoshi
    Kashiyama, Tomoko
    Ikeda, Yuji
    Nakagawa, Shunsuke
    Sone, Kenbun
    Miyamoto, Yuichiro
    Hiraike, Haruko
    Tanikawa, Michihiro
    Miyasaka, Aki
    Koso, Takahiro
    Matsumoto, Yoko
    Wada-Hiraike, Osamu
    Kawana, Kei
    Kuramoto, Hiroyuki
    McCormick, Frank
    Aburatani, Hiroyuki
    Yano, Tetsu
    Kozuma, Shiro
    Taketani, Yuji
    PLOS ONE, 2012, 7 (05):
  • [38] Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia
    Liu, Hongtao
    Diaz-Flores, Ernesto
    Poire, Xavier
    Odenike, Olatoyosi
    Koval, Greg
    Malnassy, Greg
    Ihonor, Pamela
    Zhang, Yanming
    Le Beau, Michelle M.
    Sharinon, Kevin
    Stock, Wendy
    BLOOD, 2010, 116 (21) : 1622 - 1622
  • [39] Synergistic anti-leukemia activity of the dual mTOR/PI3K inhibitor NVP-BEZ235 with the BCL-2 inhibitor venetoclax
    Niedermayer, A.
    Enzenmueller, S.
    Seyfried, F.
    Debatin, K. M.
    Meyer, L. H.
    KLINISCHE PADIATRIE, 2023, 235 (03): : 199 - 199
  • [40] Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
    Xin, Pengliang
    Li, Chuntuan
    Zheng, Yan
    Peng, Qunyi
    Xiao, Huifang
    Huang, Yuanling
    Zhu, Xiongpeng
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1115 - 1126
12345